Anterior Vitreous Migration After 0.1cc Intravitreal Injection
DOI:
https://doi.org/10.62856/djcro.v7.33Keywords:
vitreous prolapse, Intravitreal injection, complications, anterior chamber complications, aflibercept, amdAbstract
Intravitreal injection of anti-vascular endothelial growth factor agents such as aflibercept, bevacizumab, and ranibizumab are common treatments for retinal edema and neovascularization related to a number of retinal diseases such as age-related macular degeneration (AMD), retinal vein occlusion, and diabetic retinopathy. A double dose is used for refractory cases where standard dosing is insufficient to control disease progression. We present a case of a rare and potentially serious complication: vitreous prolapse into the anterior chamber following a double dose of intravitreal aflibercept injection. This case highlights the importance of close monitoring for patients who receive intravitreal injections, especially those that receive larger doses of medication.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
The Contributor assigns to Duke, during the full term of copyright and any extensions or renewals, all copyright in and to the Manuscript, and all rights therein, including but not limited to the right to publish, republish, transmit, sell, distribute and otherwise use the Manuscript in whole or in part in electronic editions of the DJCRO and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so. "Manuscript" means the article submitted by the Contributor for publication in the DJCRO (including any embedded rich media) and all subsequent versions. The definition of Manuscript does not extend to any supporting information submitted with or referred to in the Manuscript ("Supporting Information"). To the extent that any Supporting Information is submitted to the DJCRO, Duke is granted a perpetual, non-exclusive license to publish, republish, transmit, sell, distribute and otherwise use this Supporting Information in whole or in part in electronic and print editions of the DJCRO and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so. If the Manuscript was shared as a preprint, the Contributor grants to Duke exclusivity as to any rights retained by the Contributor in the preprint.
Reproduction, posting, transmission or other distribution or use of the final Manuscript in whole or in part in any medium by the Contributor as permitted by this Agreement requires a citation to the DJCRO suitable in form and content as follows: (Contributor(s), Title of Manuscript, Journal Title, Journal Volume, Copyright© [year], Digital Object Identifier [DOI] link to final Manuscript). Links to the final article on the DJCRO website are also encouraged where appropriate.
